All Journals > Clinical Infectious Diseases > 15 July 2006 > Nevirapine Levels and 24‐Week Efficacy

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 July 2006

Volume 43, Number 2
Clinical Infectious Diseases 2006;43:253–255
© 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2006/4302-0019$15.00
DOI: 10.1086/505210
HIV/AIDS BRIEF REPORT

Plasma Nevirapine Levels and 24‐Week Efficacy in HIV‐Infected Patients Receiving Nevirapine‐Based Highly Active Antiretroviral Therapy with or without Rifampicin

Weerawat Manosuthi,1

Somnuek Sungkanuparph,2

Ammarin Thakkinstian,3

Sasivimol Rattanasiri,3

Achara Chaovavanich,1

Wisit Prasithsirikul,1

Sirirat Likanonsakul,1 and

Kiat Ruxrungtham4

1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 2Faculty of Medicine and 3Clinical Epidemiology Unit, Ramathibodi Hospital, Mahidol University, and 4HIV Netherlands‐Australia‐Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Seventy human immunodeficiency virus (HIV)–infected patients receiving rifampicin and 70 HIV‐infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine‐based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin ( ). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups ( ).

Received 9 January 2006; accepted 20 March 2006; electronically published 12 June 2006.

Reprints or correspondence: Dr. Weerawat Manosuthi, Dept. of Medicine, Bamrasnaradura Infectious Diseases Institute, Tiwanon Rd., Nonthaburi, 11000, Thailand ().

Cited by

Weerawat Manosuthi, Somnuek Sungkanuparph, Preecha Tantanathip, Aroon Lueangniyomkul, Wiroj Mankatitham, Wisit Prasithsirskul, Sunantha Burapatarawong, Supeda Thongyen, Sirirat Likanonsakul, Unchana Thawornwa, Vilaiwan Prommool, and Kiat Ruxrungtham, for the N2R Study Team. (2009) A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study. Clinical Infectious Diseases 48:12, 1752-1759
Online publication date: 15-Jun-2009.
Abstract-Full Text-PDF Version (308 kB)
Doaa Elsherbiny, Karen Cohen, Britt Jansson, Peter Smith, Helen McIlleron, Ulrika S. H. Simonsson. (2009) Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. European Journal of Clinical Pharmacology 65:1, 71-80
Online publication date: 1-Feb-2009.
CrossRef
Soumya Swaminathan, G. Narendran. (2008) HIV and tuberculosis in India. Journal of Biosciences 33:4, 527-537
Online publication date: 1-Dec-2008.
CrossRef
Kelly E. Dooley, Charles Flexner, and Adriana S. Andrade. (2008) Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti‐Infective Agents: Repercussions for Resource‐Limited Countries. The Journal of Infectious Diseases 198:7, 948-961
Online publication date: 1-Oct-2008.
Citation-Full Text-PDF Version (185 kB)
William J. BURMAN. (2008) Treatment of HIV-related tuberculosis-unresolved issues. Respirology 13, S88-S99
Online publication date: 1-Oct-2008.
CrossRef
W Manosuthi, W Mankatitham, A Lueangniyomkul, S Chimsuntorn, S Sungkanuparph. (2008) Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Medicine 9:5, 294-299
Online publication date: 1-Jun-2008.
CrossRef
Stephen D Lawn, David J Edwards, Robin Wood. (2007) Concurrent drug therapy for tuberculosis and HIV infection in resource-limited settings: present status and future prospects. Future HIV Therapy 1:4, 387-398
Online publication date: 1-Dec-2007.
CrossRef
Padmini Srikantiah, Maria N Walusimbi, H Kose Kayanja, Harriet Mayanja-Kizza, Roy D Mugerwa, Royce Lin, Edwin D Charlebois, W Henry Boom, Christopher C Whalen, Diane V Havlir. (2007) Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS 21:14, 1972-1974
Online publication date: 1-Oct-2007.
CrossRef
Weerawat Manosuthi, Kiat Ruxrungtham, Sirirat Likanonsakul, Wisit Prasithsirikul, Yaowarat Inthong, Thanongsri Phoorisri, and Somnuek Sungkanuparph. (2007) Nevirapine Levels after Discontinuation of Rifampicin Therapy and 60‐Week Efficacy of Nevirapine‐Based Antiretroviral Therapy in HIV‐Infected Patients with Tuberculosis. Clinical Infectious Diseases 44:1, 141-144
Online publication date: 1-Jan-2007.
Abstract-Full Text-PDF Version (88 kB)
Weerawat Manosuthi, Suthat Chottanapand, Supeda Thongyen, Achara Chaovavanich, Somnuek Sungkanuparph. (2006) Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 43:1, 42-46
Online publication date: 1-Oct-2006.
CrossRef
Ronan A M Breen, Leonie Swaden, Jayne Ballinger, Marc C I Lipman. (2006) Tuberculosis and HIV Co-Infection. Drugs 66:18, 2299-2308
Online publication date: 1-Feb-2006.
CrossRef

  • Presented in part: 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, Washington DC, 2005 (abstract H‐414).

Back to Top
Close Popup